SEHK:9969Biotechs
First Solid-Tumor Drug Approval Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)
In the past week, InnoCare Pharma reported China NMPA approval of zurletrectinib (ICP-723) for NTRK fusion-positive solid tumors in patients aged 12 and above, alongside strong efficacy and safety data, while also showcasing extensive positive clinical results for orelabrutinib and mesutoclax at the ASH 67th Annual Meeting.
This marks InnoCare’s first approved solid-tumor therapy, adding a blood–brain-barrier-penetrant TRK inhibitor to its portfolio and underscoring its push to build a broad...